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Abstract
Atherosclerosis is characterised by the growth of fatty plaques in the inner (intimal)
layer of the artery wall. In mature plaques, vascular smooth muscle cells (SMCs) are
recruited from the adjacent medial layer to deposit a cap of fibrous collagen over the
fatty plaque core. The fibrous cap isolates the thrombogenic content of the plaque
from the bloodstream and prevents the formation of blood clots that cause myocardial
infarction or stroke. Despite the important protective role of the cap, the mechanisms
that regulate cap formation and maintenance are not well understood. It remains
unclear why certain caps become stable, while others become vulnerable to rupture.
We develop a multiphase PDE model with non-standard boundary conditions to
investigate collagen cap formation by SMCs in response to growth factor signals from
the endothelium. Diffusible platelet-derived growth factor (PDGF) stimulates SMC
migration, proliferation and collagen degradation, while diffusible transforming growth
factor (TGF)-β stimulates SMC collagen synthesis and inhibits collagen degradation.
The model SMCs respond haptotactically to gradients in the collagen phase and have
reduced rates of migration and proliferation in dense collagenous tissue. The model,
which is parameterised using a range of in vivo and in vitro experimental data, re-
produces several observations from studies of plaque growth in atherosclerosis-prone
mice. Numerical simulations and model analysis demonstrate that a stable cap can be
formed by a relatively small SMC population and emphasise the critical role of TGF-
β in effective cap formation and maintenance. These findings provide unique insight
into the cellular and biochemical mechanisms that may lead to plaque destabilisation
and rupture. This work represents an important step towards the development of a
comprehensive in silico plaque.
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1 Introduction
Cardiovascular diseases are the leading global cause of mortality (World Health Organization,
2017). Atherosclerosis, the growth of fat-filled plaques in the walls of arteries, is the primary
cause of most cardiovascular disease-related deaths. Unstable atherosclerotic plaques can
rupture, and subsequent blood clot formation may occlude blood flow and lead to myocar-
dial infarction or stroke (Hansson and Libby, 2006). Smooth muscle cells (SMCs) play an
important role in the prevention of these grave clinical outcomes by forming a stabilising cap
of fibrous tissue over the lipid-rich core in developing plaques (Alexander and Owens, 2012).
To understand how plaques become unstable and dangerous, it is important to understand
the behaviour of plaque SMCs and the corresponding mechanisms of fibrous cap synthesis
or degradation. Despite extensive experimental investigation, the in vivo dynamics of cap
formation remain poorly understood.
The absence of a dynamic understanding of cap formation and maintenance can be largely
attributed to the slow rate of plaque development. In humans, atherosclerosis can begin in
childhood and plaques may take several decades to progress towards a dangerous, unstable
state (Lusis, 2000). Even in the apolipoprotein-E (ApoE) deficient mouse (the most common
animal model for experimental atherosclerosis studies), plaques require a period of several
months to grow to an advanced stage. Consequently, observations of plaque tissue resected
from experimental mice are typically made at distinct (or even single) time points. Mathe-
matical modelling provides a powerful tool to study the dynamic mechanisms that underlie
these patchy experimental observations. In this paper, we use the multiphase framework de-
veloped in Watson et al. (2018) and build a comprehensive new model to study the formation
of the protective fibrous cap by atherosclerotic plaque SMCs.
Atherosclerotic plaques develop in the narrow intimal layer of the artery wall (Figure 1).
The intima is located between the endothelium (a thin sheet of endothelial cells that lines the
vessel lumen) and the media, which houses several striated layers of quiescent (contractile)
SMCs. The intima and the media are separated by a dense tissue membrane known as the
internal elastic lamina (IEL). The outermost layer of the artery wall beyond the media is
called the adventitia. Plaque formation is initiated by blood-borne low-density lipoproteins
(LDL), which accumulate in the intima and become oxidised or modified in different ways.
The presence of modified LDL triggers the recruitment of immune cells (monocytes) from
the bloodstream by a process of transendothelial migration. These monocytes differentiate
into macrophages, which can consume the lipid and remove it from the intima by migration
to the adventitial lymphatics (Moore et al., 2013). However, when lipid-filled macrophages
(known as foam cells) die within the plaque, they release their lipid content and other cellular
debris. This reinforces the immune response and can lead to a cycle of chronic inflammation
that promotes plaque growth and, ultimately, the development of necrotic tissue.
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Figure 1: Schematic diagram of a cross-section through the inner artery wall (layer widths
not to scale and outer adventitial layer not shown). Atherosclerotic plaques develop in the
intima, which is separated from the blood flow in the lumen by a thin layer of cells called
the endothelium. Deeper in the wall, the intima is separated from the media by a membrane
called the internal elastic lamina.
At an intermediate stage of plaque formation, medial SMCs adopt an active (synthetic)
state and migrate through the IEL into the intima. SMC activation is believed to be initiated
by an injured endothelium, which may suffer mechanical disruption as the intimal layer ex-
pands to accommodate the infiltration of lipid and immune cells (Faggiotto and Ross, 1984).
Once inside the plaque, SMCs replace the existing intimal extracellular matrix (ECM) with
a dense matrix of fibrillar collagens (Adiguzel et al., 2009). SMCs are subject to an abun-
dance of signalling cues in the plaque, but two chemicals known to be particularly critical to
cap formation are platelet-derived growth factor (PDGF) and transforming growth factor-β
(TGF-β). PDGF plays an important role as a SMC mitogen and chemoattractant (Ruther-
ford et al., 1997; Sano et al., 2001), while TGF-β enhances plaque stability by stimulating
SMC collagen production (Mallat et al., 2001; Lutgens et al., 2002). PDGF and TGF-β
can be produced by a variety of plaque cells, but circulating platelets that adhere to sites
of endothelial injury are believed to be a significant source of both growth factors (Ross,
1999; Toma and McCaffrey, 2012). TGF-β is secreted as a latent complex and the active
component of TGF-β must be liberated before it can bind to target cells (Singh and Ramji,
2006). Liberation of active TGF-β typically requires chemical or mechanical stimulation,
and TGF-β derived from platelets is believed to be activated by shear forces in the blood-
stream (Ahamed et al., 2008). A schematic diagram of the cap formation process is provided
in Figure 2.
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Figure 2: Schematic diagram of the key processes in atherosclerotic cap formation. Lipopro-
tein accumulation in the intima triggers an immune response that leads to intimal growth
and endothelial disruption. Diffusible growth factors PDGF and TGF-β are released from
sites of injury by endothelial cells and adherent platelets. Contractile SMCs in the media are
stimulated to adopt a synthetic state and respond chemotactically to PDGF by migrating
through the internal elastic lamina. Once inside the plaque, synthetic SMCs remodel the
existing ECM and are stimulated by TGF-β to deposit a dense cap of collagenous tissue
adjacent to the endothelium.
Recent advances in cell lineage tracing techniques have begun to reveal new insights
into the behaviour of plaque SMCs. Chappell et al. (2016) and Jacobsen et al. (2017)
have performed studies using so-called Confetti transgenic mice, where individual medial
SMCs can be labelled by inducing the unique expression of one of four possible fluorescent
proteins in each cell. Both of these studies have identified that SMC populations in advanced
plaques consist of several large monochromatic patches, indicating that plaque SMCs are
oligoclonal and derived from only a limited number of medial progenitor cells. These results
are significant because they highlight, in the ApoE mouse at least, that proliferation makes
a much larger contribution to SMC accumulation in plaques than previously thought.
These studies provide an exciting new window into the cellular mechanisms of fibrous cap
formation, and have significant potential to advance current understanding of atherosclerosis
progression. However, much is still unknown about the factors that underlie the formation
and maintenance of the collagenous cap and, in particular, the reasons why certain caps
remain thick and stable whilst others become thin and vulnerable to rupture. Several possible
modes of long-term cap degradation have been proposed in the literature. These include an
increase in SMC death — possibly due to cellular senescence (Wang et al., 2015) — or
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an increase in collagen destruction due to either elevated matrix metalloproteinase (MMP)
production by inflammatory cells (Hansson et al., 2015) or reduced SMC sensitivity to TGF-
β signalling (Chen et al., 2007; Vengrenyuk et al., 2015). The model that we develop in
this paper addresses these gaps in biological understanding by establishing a framework to
simulate cap formation dynamics and assess the deleterious impact of a variety of ECM
degradation mechanisms.
We have recently published a foundational two-phase PDE model that studied the migra-
tion and proliferation of media-derived SMCs in response to an endothelium-derived source of
diffusible PDGF (Watson et al., 2018). The model domain was taken to be a one-dimensional
cross-section through the diseased intima and the flux of SMCs and PDGF into the plaque
were captured by a set of non-standard boundary conditions. The model did not explicitly
consider the synthesis of a fibrous cap, but the approach did provide several interesting in-
sights into the mechanisms that regulate SMC migration to the cap region. In particular, the
model predicted that SMC recruitment from the media is likely to be a rate-limiting factor
for SMC accumulation in plaques — an observation that is supported by the recent lineage
tracing studies of Chappell et al. (2016) and Jacobsen et al. (2017). In the current paper,
we build upon this earlier model by incorporating a profile of diffusible, endothelium-derived
TGF-β and an explicit representation of collagenous ECM remodelling. This allows us to
perform a detailed investigation of growth factor-stimulated fibrous cap formation by plaque
SMCs. Note that the new model is more than just an elementary extension of the earlier
approach. We assume that the SMCs and the nascent ECM are coupled by a nonlinear me-
chanical feedback that allows us to investigate the influence of factors including haptotactic
SMC migration, which may play an important role in the cap formation process (Nelson
et al., 1996; Lopes et al., 2013).
Interest in mathematical modelling of the cell activity in atherosclerosis has grown over
recent years. The majority of studies published to date have focussed on modelling the
inflammatory response that characterises the early stages of plaque development (El Khatib
et al., 2007; Pappalardo et al., 2008; Cohen et al., 2014; Chalmers et al., 2015), where
several groups have coupled their models to detailed representations of blood flow and/or
intimal growth (Bulelzai and Dubbeldam, 2012; Filipovic et al., 2013; Islam and Johnston,
2016; Yang et al., 2016; Bhui and Hayenga, 2017). In contrast, only a handful of models
have been proposed to study events in the later stages of plaque progression. McKay et al.
(2004) performed foundational work in this area by proposing a PDE model that included
both plaque SMC recruitment and subsequent collagen deposition. The only other model to
consider collagen synthesis by invading SMCs is that of Cilla et al. (2014), who developed a
comprehensive 3D model of blood flow, transmural transport and plaque growth. Neither of
these modelling approaches, however, provide an adequate description of the cap formation
process. Several other models of plaque progression (Poston and Poston, 2007; Friedman
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and Hao, 2015) — including studies of PDGF-induced intimal thickening (Fok, 2012) and
intraplaque haemorrhage (Guo et al., 2018) — have considered SMCs independently of their
collagen-synthesising activity. Interested readers are referred to Parton et al. (2016) for
a comprehensive review of mathematical and computational approaches to atherosclerosis
modelling.
Beyond atherosclerosis, a variety of mathematical models have been developed to study
the response of vascular SMCs to other sources of endothelial injury. One area that has at-
tracted significant research interest is in-stent restenosis — the rapid recurrence of a narrowed
lumen after surgical deployment of an artery-widening stent. Mechanical stresses imposed
by the stent can locally denude the endothelium and elicit an intense healing response that
involves rapid proliferation of medial SMCs and significant neointima formation. Discrete
and continuous models of SMC behaviour during in-stent restenosis have been developed
by several research groups (Lally and Prendergast, 2006; Evans et al., 2008; Zahedmanesh
et al., 2014; Tahir et al., 2015). Researchers have also developed models of the vascular
SMC response to surgical interventions such as vein grafting (Budu-Grajdeanu et al., 2008;
Garbey et al., 2017) and blood filter insertion (Nicolas et al., 2015). The tissue repair carried
out by artery wall SMCs in response to vascular injury also shares several similarities with
the process of dermal wound healing. In dermal wounds, fibroblasts take the role of the
SMC and migrate to the wound site to regenerate the damaged collagenous tissue. Wound
fibroblasts are known to be stimulated by growth factors including PDGF and TGF-β, and
the corresponding implications for healing have been studied in a variety of modelling frame-
works (Olsen et al., 1995; Cobbold and Sherratt, 2000; Haugh, 2006; McDougall et al., 2006;
Cumming et al., 2010; Menon et al., 2012).
The model of cap formation that we present in this paper is inspired by the multiphase
theory developed in Byrne and Owen (2004), Lemon et al. (2006) and Astanin and Preziosi
(2008). Multiphase models have been widely developed to study articular cartilage (reviewed
in Klika et al. (2016)), tumour growth (Preziosi and Tosin, 2009; Hubbard and Byrne, 2013)
and tissue engineering applications (O’Dea et al., 2013; Pearson et al., 2014), but our previous
study (Watson et al., 2018) was the first application of the approach in atherosclerosis.
Other existing studies of plaque development have predominantly utilised reaction-diffusion
equations to model the spatio-temporal evolution of cells and tissues in the plaque (McKay
et al., 2004; El Khatib et al., 2007; Filipovic et al., 2013; Cilla et al., 2014; Chalmers et al.,
2015, 2017). However, multiphase models can provide a more detailed representation of
plaque formation dynamics because they provide a natural framework to account for volume
exclusion and mechanical interactions between individual plaque constituents. We continue
to develop our multiphase approach in this study because we firmly believe that both volume
exclusion and mechanical effects can play a significant role in the development of plaque
spatial structure.
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In the next section, we derive the model equations and introduce the model parameterisa-
tion. Where possible, we base our assumptions and our parameter selections on observations
of plaque growth in the ApoE mouse, which is the most well-characterised animal model of
in vivo atherosclerosis in the experimental literature (Getz and Reardon, 2012). We present
the model results in Section 3, where we report some interesting analysis before performing
a series of numerical simulations. We use these results to investigate the dynamic cellular,
biochemical and mechanical mechanisms that regulate cap formation and aim to identify the
factors that are most important to the development and maintenance of plaque stability.
Finally, we conclude with a discussion of the outcomes of the study in the context of both
computational and experimental atherosclerosis research.
2 Model Formulation and Parameterisation
The plaque tissue in the model is represented as a mixture of three distinct phases: a cellular
phase that comprises matrix-synthesising SMCs, an ECM phase that comprises collagen-rich
fibrous tissue, and a generic phase that is assumed to comprise the remaining plaque con-
stituents (foam cells, extracellular lipids, interstitial fluid, etc.). We derive mass and mo-
mentum balance equations for each phase, and the equations are closed by imposing suitable
constitutive assumptions and conditions for the transfer of mass and momentum between
each pair of phases. Equations for the concentrations of diffusible PDGF and (active) TGF-β
are also included in the model. We assume that PDGF promotes a migroproliferative SMC
phenotype, while TGF-β promotes a matrigenic SMC phenotype (Alexander and Owens,
2012). These distinct SMC phenotypes are not explicitly represented in the model. Instead,
we assume that the SMC phase contains a continuum of different phenotypes whose aver-
age behaviour is regulated by the local growth factor concentrations. We assume that both
PDGF and TGF-β reside exclusively in the generic tissue phase, and that they exert influ-
ence on the SMC and ECM phases via stress and/or mass transfer terms that are functions
of their respective concentrations.
We model the above system on a one-dimensional Cartesian domain that represents a
cross-section of diseased arterial intima far from the edges of the plaque. We assume that the
domain is bounded by the endothelium at x = 0 and by the IEL at x = L. The dependent
variables are therefore functions of time t > 0 and position x ∈ [0, L]. We denote the volume
fractions of the SMC, ECM and generic tissue phases by m (x, t), ρ (x, t) and w (x, t), and
their corresponding intraphase stresses by τm (x, t), τρ (x, t) and τw (x, t), respectively. We
assume that the ECM phase takes the form of a rigid scaffold and the ECM phase therefore
has zero velocity for all x and t. We denote the (non-zero) velocities of the SMC and generic
tissue phases by vm (x, t) and vw (x, t). The interstitial fluid pressure is denoted by p (x, t),
and the concentrations of PDGF and TGF-β in the generic tissue phase are denoted by
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P (x, t) and T (x, t), respectively.
2.1 SMC, ECM and Generic Tissue Phases
In this section we use the principles of mass and momentum conservation to derive equations
that describe the SMC, ECM and generic tissue phase dynamics in response to diffusible
PDGF and TGF-β in the plaque.
2.1.1 Mass Balance Equations
Assuming that all three phases share the same constant density, the mass balance equations
for m, ρ and w can be expressed as follows:
∂m
∂t
+
∂
∂x
(vmm) = Sm, (1)
∂ρ
∂t
= Sρ, (2)
∂w
∂t
+
∂
∂x
(vww) = − (Sm + Sρ) . (3)
Here, the functions Sm and Sρ represent the net rates of SMC and ECM production. We
have assumed in equation (3) that there is no local source or sink of material and that
mass simply transfers from one phase to another as SMCs proliferate or die, and as ECM
is synthesised or degraded. We further assume that there are no voids in the plaque tissue,
and the three volume-occupying phases therefore satisfy the condition:
m+ ρ+ w = 1. (4)
2.1.2 Momentum Balance Equations and Constitutive Assumptions
Neglecting inertial effects and assuming that no external forces act on the system, the mo-
mentum balance equations for m, ρ and w reduce to a balance between the intraphase and
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interphase forces that act on each phase:
∂
∂x
(τmm) = Fρm + Fwm, (5)
∂
∂x
(τρρ) = Fmρ + Fwρ, (6)
∂
∂x
(τww) = Fmw + Fρw, (7)
where Fij (= −Fji) denotes the force exerted by phase j on phase i.
Following Lemon et al. (2006), we assume that the Fij terms in equations (5)–(7) are
comprised of interphase pressure and interphase drag components:
Fmρ = (p+ ψ) ρ
∂m
∂x
− (p+ ψ)m ∂ρ
∂x
− kmρmρvm, (8)
Fmw = pw
∂m
∂x
− pm ∂w
∂x
+ kmwmw (vw − vm) , (9)
Fρw = pw
∂ρ
∂x
− pρ ∂w
∂x
+ kρwρwvw. (10)
The first term on the right hand side of each of equations (8)–(10) describes the interfacial
force exerted by phase j on phase i. This force is assumed to be proportional to the interphase
pressure between the phases and to the degree of contact of phase j with phase i. The force
is assumed to act in the direction of increasing interfacial contact and, on the macroscale,
this contributes a further term proportional to the gradient in phase i. The second term
on the right hand side of each equation contributes a corresponding reaction force, which is
exerted by phase i on phase j. Note that we have included an additional (contact-dependent)
interphase pressure contribution ψ ≡ ψ (m, ρ) in the equation for Fmρ. This additional
pressure is included to account for traction forces that are generated as the SMCs translocate
through the ECM. We assume that traction forces between the other pairs of phases in the
system are negligible in comparison, so the equations for Fmw and Fρw include only the
contact-independent pressure p in their interphase pressure terms. The final term on the
right hand side of each equation represents the interphase drag, which we assume to be
proportional to the relative velocities of phases i and j with constant of proportionality
kij (= kji). We further assume that the drag depends linearly on the volume fraction of each
phase i and j so that no drag can occur in the absence of either phase.
The generic tissue phase contains several active constituents such as foam cells and
macrophages, but we shall assume here that it behaves as an inert isotropic fluid. We
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make this assumption in order to focus on how the SMC phase interacts with other key
factors in the plaque environment. We shall assume that the SMC phase displays more
complex behaviour than the generic tissue phase and, in particular, that SMCs alter their
motility in response to both the local PDGF concentration and the local ECM volume frac-
tion. Neglecting viscous effects, and combining the approaches of Byrne and Owen (2004)
and Lemon et al. (2006), we adopt the following models for the intraphase stress terms in
equations (5)–(7):
τm = − [ p+ ρψ (m, ρ) + Λ(P ) ] , (11)
τρ = − [ p+mψ (m, ρ) ] , (12)
τw = − p. (13)
In equation (11), the extra pressures Λ(P ) and ρψ (m, ρ) describe the respective influences of
the PDGF concentration and the ECM volume fraction on the pressure in the SMC phase.
The ECM-derived extra pressure term is proportional to the interphase pressure contribution
ψ and is weighted according to the degree of contact between the SMC and ECM phases.
We assume that the SMC phase has a complementary influence on the pressure in the ECM
phase, and this is captured by the extra pressure term mψ (m, ρ) in equation (12). We define
the functions Λ and ψ to be (Byrne and Owen, 2004; Lemon et al., 2006):
Λ(P ) =
χP
1 + (κP )nP
, (14)
ψ (m, ρ) = −χρ + δm
nρ
(1−m− ρ)nρ , (15)
where χP , κ, nP , χρ, δ and nρ are positive parameters. Equation (14) is deliberately chosen
to be a decreasing function of P as this ensures that chemotactic SMC migration up PDGF
gradients will provide stress relief in the SMC phase. The first term in equation (15), which
ensures that ψ will be negative for sufficiently small m, reflects an assumption that the SMCs
have an affinity for the collagenous ECM. Note that this adhesion mechanism introduces the
potential for haptotactic SMC migration in the presence of ECM gradients. The second term
in equation (15) contributes a net repulsion on the SMC phase that increases significantly
as m or ρ become sufficiently large.
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2.1.3 Mass Transfer Terms
We assume that the SMC phase source term Sm in equation (1) includes both a linear death
term and a proliferation term that requires the uptake of material from the generic tissue
phase. We assume that the net SMC proliferation rate is proportional to the sum of a
constant baseline mitosis rate rm and an additional rate that depends on the local PDGF
concentration. PDGF is a well-known mitogen for SMCs, and in vitro evidence suggests that
SMC proliferation can be significantly upregulated with saturating kinetics in the presence
of increasing PDGF concentrations (Munro et al., 1994). Combining these considerations,
we define:
Sm = rmmw
[
1 +
AmP
cm + P
]
− βmm, (16)
where Am quantifies the maximum possible PDGF-stimulated increase in the baseline SMC
mitosis rate, cm represents the PDGF concentration at which the half-maximal increase in
the baseline SMC mitosis rate occurs, and βm denotes the rate of SMC death. We remark
here that, while normal vascular SMCs are known to be growth inhibited by TGF-β, in vitro
experiments have shown that atherosclerotic plaque-derived SMCs retain their proliferative
capacity in the presence of TGF-β (McCaffrey et al., 1995).
We define the ECM phase source term Sρ in equation (2) by assuming that the collagenous
matrix is continuously remodelled by the cells that occupy the plaque. Based on a variety of
experimental observations, we assume that both PDGF and TGF-β are important mediators
of this remodelling process. We propose the following form for the ECM phase source term,
where we assume that ECM is synthesised by SMCs but is also degraded by both SMCs and
plaque immune cells:
Sρ = rsmw
[
1 +
AsT
cs + T
]
− rdmρ
[
1 +
AdP
(cd + P ) (1 + γdT )
]
− βρρw
[
1 + ε γρT
1 + γρT
]
. (17)
The first term in equation (17) represents the net rate of ECM synthesis by the SMC
phase, which we assume to be proportional to the sum of a constant baseline ECM produc-
tion rate rs and an additional rate that depends on the local TGF-β concentration. The role
of TGF-β as a stimulant for SMC collagen production in plaques has been clearly demon-
strated by in vivo studies (Mallat et al., 2001; Lutgens et al., 2002) and, following in vitro
observations (Kubota et al., 2003), we assume that the rate of ECM synthesis increases with
saturating kinetics in response to increasing T . The parameter As quantifies the maximum
possible TGF-β-stimulated increase in the baseline ECM synthesis rate, while cs denotes the
TGF-β concentration at which the half-maximal increase in the baseline ECM synthesis rate
occurs. Note that the ECM synthesis rate is also proportional to w because we assume that
ECM synthesis by SMCs again requires the uptake of material from the generic tissue phase.
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The second and third terms in equation (17) represent the respective net rates of ECM
degradation by plaque SMCs and by plaque immune cells, both of which are known to pro-
duce MMPs. We assume that the net rate of ECM degradation by SMCs is proportional
to the sum of a constant baseline degradation rate rd and an additional rate that depends
on the local concentration of both growth factors. In vitro studies indicate that SMCs up-
regulate their production of MMP-2 and MMP-9 in response to stimulation with PDGF,
but also that co-stimulation with TGF-β can inhibit this response (Borrelli et al., 2006;
Risinger et al., 2010). We represent this behaviour with a simple functional form where Ad
quantifies the maximum possible PDGF-stimulated increase in the baseline ECM degrada-
tion rate, cd denotes the PDGF concentration at which the half-maximal PDGF-stimulated
increase in the baseline ECM degradation rate occurs and γd quantifies the extent of inhi-
bition of PDGF-stimulated ECM degradation by TGF-β. Experimental observations also
indicate that TGF-β can protect the plaque ECM from degradation by MMP-9-producing
macrophages (Vaday et al., 2001; Ogawa et al., 2004). Assuming that macrophages and
other inflammatory cell types comprise a certain fraction of the generic tissue phase, we
capture this behaviour in the final term by assuming that the net rate of immune cell ECM
degradation is proportional to both w and a decreasing function of T . The parameter βρ
denotes the maximum possible rate of immune cell ECM degradation, which we assume to
be related to the extent of inflammation in the plaque tissue. The dimensionless parameter
ε 6 1 quantifies the minimum possible rate of TGF-β-inhibited immune cell ECM degration
(i.e. εβρ), while γρ quantifies the rate at which immune cell ECM degradation decreases with
increasing T .
2.2 Diffusible Growth Factors
In this section we derive reaction-diffusion equations that describe how the concentrations
of diffusible PDGF and TGF-β evolve in the plaque tissue. In addition to the equations
presented below, the model also includes a source term for each growth factor at the en-
dothelium (x = 0) and sink term for each growth factor at the media (x = L). These
additional terms are given by boundary conditions and will be discussed in Section 2.4.
2.2.1 Mass Balance Equations
We assume that the characteristic timescales of PDGF and TGF-β diffusion are significantly
shorter than the characteristic timescales of SMC migration and ECM remodelling. We
therefore neglect advective growth factor transport in the generic tissue phase and assume
12
the following quasi-steady state mass balance equations for P and T :
0 = DP
∂
∂x
[
w
∂P
∂x
]
+ SP , (18)
0 = DT
∂
∂x
[
w
∂T
∂x
]
+ ST . (19)
Here, DP and DT are constant chemical diffusion coefficients, while SP and ST denote local
sink terms for PDGF and TGF-β, respectively. Note that, following Astanin and Preziosi
(2008), we have assumed that the diffusive flux of both chemicals is modulated by the factor
w. This implies that the capacity for growth factor transport through the intimal tissue will
reduce as SMCs and ECM accumulate in the plaque.
2.2.2 Source Terms
We assume that both growth factors are taken up by SMCs in the plaque, and also that
both growth factors undergo natural decay. These assumptions lead to the sink terms:
SP = −ηPmwP − βPwP, (20)
ST = −ηTmwT − βTwT, (21)
where ηP , ηT , βP and βT denote the rates of PDGF uptake by SMCs, TGF-β uptake by
SMCs, PDGF decay and TGF-β decay, respectively. Note that we include a factor of w in
each term to ensure that neither uptake nor decay of either growth factor can occur in the
absence of the generic tissue phase.
2.3 Model Simplification
In this section, we show how the three-phase model developed in Section 2.1 can be reduced
to a system of two coupled nonlinear equations for the SMC and ECM phases. In all that
follows, we shall assume that the volume fractions of all three phases m, ρ and w are strictly
positive for all x and t.
Using equation (4) to replace all occurrences of w with the equivalent expression 1−m−ρ,
the sum of the mass balance equations (1)–(3) reduces to:
∂
∂x
[
vmm+ vw (1−m− ρ)
]
= 0. (22)
Assuming a zero-flux condition for the SMC phase at the endothelium (i.e. vm = vw = 0 at
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x = 0), integration of equation (22) with respect to x gives the following expression for the
velocity of the generic tissue phase:
vw = −vm
(
m
1−m− ρ
)
. (23)
Summing the momentum balance equations (5)–(7), and substituting in the expres-
sions (11)–(13) gives the following equation for the tissue pressure gradient:
∂p
∂x
= − ∂
∂x
[
m (Λ + 2ρψ)
]
. (24)
A second expression for the tissue pressure gradient is obtained by substituting the expres-
sions (9), (10) and (13) into equation (7) (note that equation (8) becomes redundant at this
juncture). Cancelling terms, we obtain:
∂p
∂x
= kmwmvm − vw (kmwm+ kwρρ) . (25)
Equating the right hand sides of equations (24) and (25), and then using equation (23) to
eliminate vw, we derive the following expression for vm in terms of m, ρ and P :
vm = −
[
1−m− ρ
kmwm (1− ρ) + kwρmρ
]
∂
∂x
[
m (Λ + 2ρψ)
]
. (26)
In the interest of simplicity, we shall assume that the drag between the generic tissue phase
and the SMC phase and between the generic tissue phase and the ECM phase is uniform
(i.e. kmw = kwρ = k). Making this simplification and substituting equation (26) back
into equation (1), we arrive at the final mass balance relationship for the SMC phase in the
intima:
∂m
∂t
=
1
k
∂
∂x
[
(1−m− ρ) ∂
∂x
[
m (Λ + 2ρψ)
] ]
+ Sm (m, ρ, P ) . (27)
Our reduced model therefore comprises equation (27) alongside the following expressions for
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Figure 3: Schematic diagram of the primary interactions that regulate fibrous cap formation
in the model. The volume-occupying phases are shown in red and the volumeless chemical
growth factors are shown in blue. Labelled (solid) lines indicate interactions that act to
increase (arrows) or decrease (bars) the SMC and ECM volume fractions in the cap region.
Unlabelled (dashed) lines denote the stimulatory (arrows) and inhibitory (bars) effects of
the growth factors on the synthesis and degradation of the ECM phase.
ρ, P and T :
∂ρ
∂t
= Sρ (m, ρ, P, T ) , (28)
0 = DP
∂
∂x
[
(1−m− ρ) ∂P
∂x
]
+ SP (m, ρ, P ) , (29)
0 = DT
∂
∂x
[
(1−m− ρ) ∂T
∂x
]
+ ST (m, ρ, T ) . (30)
A schematic diagram that summarises the key model interactions involved in fibrous cap
formation is provided in Figure 3.
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2.4 Boundary and Initial Conditions
In this section we define the boundary conditions required to solve equations (27), (29)
and (30), and the initial conditions required to solve equations (27) and (28). Note that
the assumptions that we make are largely consistent with those made previously in Watson
et al. (2018).
Recall that in the model simplification in Section 2.3 we have already assumed a zero-flux
condition for SMCs at the endothelium. We therefore have the following boundary condition
for the SMC phase:
1
k
(1−m− ρ) ∂
∂x
[
m (Λ + 2ρψ)
]
= 0 at x = 0
=⇒ ∂
∂x
[
m (Λ + 2ρψ)
]
= 0 at x = 0. (31)
Note that, in practice, this boundary condition stipulates that any flux of SMCs towards
the endothelium at x = 0 must be identically balanced by an equivalent flux of SMCs in the
opposite direction.
SMC invasion of the plaque requires the activation of quiescent SMCs in the media by
chemical signalling, and subsequent production of progeny that can negotiate the porous
IEL (Chappell et al., 2016; Jacobsen et al., 2017). The IEL provides a physical barrier to
cell movement, so it is likely that a sustained and directed migratory response is required
for synthetic SMCs to enter the plaque. We therefore assume that chemotaxis is the domi-
nant mechanism of SMC migration across the IEL, and that any contribution from passive
SMC diffusion or from ECM-mediated haptotaxis is negligible. We introduce the parameter
mM < 1 to represent a constant volume fraction of activated medial SMCs, and assume
a chemotactic flux of these cells into the intima in response to the PDGF gradient at the
medial boundary:
1
k
(1−m− ρ) ∂
∂x
[
m (Λ + 2ρψ)
]
=
1
k
(1−m− ρ) dΛ
dP
mM
∂P
∂x
at x = L
=⇒ ∂
∂x
[
m (Λ + 2ρψ)
]
=
dΛ
dP
mM
∂P
∂x
at x = L. (32)
There are several points to note regarding the format of this boundary condition. First, the
model assumes that no SMCs will enter the intima in the absence of a PDGF gradient at
the medial boundary. Second, the condition does not stipulate continuity of m across the
boundary (i.e. in general, m 6= mM at x = L). Finally, since we are assuming a closed system,
the boundary condition implies that any flux of SMCs into the intima must be balanced by
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an equivalent efflux from the generic tissue phase into the media. Such an efflux of tissue
constituents such as macrophages and foam cells may not be entirely physically realistic,
but we resolve that our modelling assumptions remain reasonable provided that the total
influx of plaque SMCs remains relatively small. An extended model that explicitly captures
intimal growth could, of course, provide a more comprehensive treatment of the problem.
However, we postpone modelling of domain growth for future work because we believe that
the current approach provides significant insight into the cap formation process without the
added complexity of tracking a moving boundary.
Stimulated endothelial cells and adherent platelets at the lesion site are believed to be
the dominant sources of PDGF in the plaque (Funayama et al., 1998), and we model this
influx of endothelium-derived PDGF with the following boundary condition:
DP (1−m− ρ) ∂P
∂x
= −αP (1−m− ρ) at x = 0
=⇒ ∂P
∂x
= − αP
DP
at x = 0, (33)
where αP quantifies the rate of PDGF flux into the intima, and the term (1−m− ρ) is
included for consistency with the modulated PDGF transport inside the model domain. Note
the corresponding implication that the absolute rate of PDGF influx into the plaque will
reduce as the SMC and ECM phases accumulate at the luminal boundary. This introduces an
implicit self-regulation mechanism in the model whereby SMCs can effectively downregulate
the signal that recruits them to the cap region.
The boundary condition (32) stipulates that SMC migration into the plaque from the
media requires a negative PDGF gradient at the medial boundary. We therefore treat the
IEL as a permeable membrane and assume that PDGF can diffuse into the media from the
intima according to the following boundary condition:
DP (1−m− ρ) ∂P
∂x
= σP (PM − P ) (1−m− ρ) at x = L
=⇒ ∂P
∂x
=
σP
DP
(PM − P ) at x = L. (34)
Here, σP denotes the permeability of the IEL to PDGF, PM represents the PDGF concen-
tration in the media, and the term (1−m− ρ) is again included for consistency with the
modulated chemical transport inside the domain.
The boundary conditions that we impose for TGF-β take an identical format to those
defined for PDGF. Like PDGF, TGF-β is also released by degranulating platelets and acti-
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vated endothelial cells at the lesion site (Toma and McCaffrey, 2012). We therefore define
the following condition at the endothelium:
DT (1−m− ρ) ∂T
∂x
= −αT (1−m− ρ) at x = 0
=⇒ ∂T
∂x
= − αT
DT
at x = 0, (35)
where αT quantifies the rate of TGF-β flux into the intima. At the medial boundary, we
assume:
DT (1−m− ρ) ∂T
∂x
= σT (TM − T ) (1−m− ρ) at x = L
=⇒ ∂T
∂x
=
σT
DT
(TM − T ) at x = L, (36)
where σT denotes the permeability of the IEL to TGF-β, and TM represents the TGF-β
concentration in the media. Note that the decision to allow TGF-β to diffuse out of the
domain is made simply for consistency with the boundary condition (34) for PDGF. The
presence of an explicit TGF-β gradient at the medial boundary is not required to initiate
cap formation in the model.
Finally, we must define initial profiles for the SMC and collagenous ECM phases in the
plaque. Observations of plaque development in mice indicate that the SMC population in
the intima is negligible prior to cap formation (Bennett et al., 2016). The model equations
cannot support a domain that is entirely devoid of SMCs (see the singularity that arises in
equation (26), for example), so we initiate the plaque with a small and uniform initial SMC
volume fraction:
m (x, 0) = mi, where 0 < mi  1. (37)
We also assume a small and uniform initial profile for the collagenous ECM phase in the
plaque:
ρ (x, 0) = ρi, where 0 < ρi  1. (38)
This initial collagen is assumed to represent a fraction of the ECM that exists in the
intima prior to SMC invasion. The remaining constituents of the initial plaque ECM, whose
quantities we do not explicitly track, are assumed to reside in the generic tissue phase and
are notionally replaced by the deposition of new collagen over the course of a simulation.
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2.5 Model Non-Dimensionalisation
Using tildes to denote dimensionless quantities, we rescale space x, time t, PDGF concen-
tration P and TGF-β concentration T as follows (note that the SMC volume fraction m and
the ECM volume fraction ρ do not require rescaling):
x˜ =
x
L
, t˜ =
t
t0
, P˜ =
P
P0
, T˜ =
T
T0
, m˜ = m, ρ˜ = ρ,
where t0, P0 and T0 represent characteristic time, PDGF concentration and TGF-β concen-
tration values, respectively. The model parameters can now be non-dimensionalised in the
following way:
χ˜P =
χP t0
kL2
, κ˜ = κP0, χ˜ρ =
2χρt0
kL2
, δ˜ =
2δt0
kL2
, r˜m = rmt0,
c˜m =
cm
P0
, β˜m = βmt0, r˜s = rst0, c˜s =
cs
T0
, r˜d = rdt0,
c˜d =
cd
P0
, γ˜d = γdT0, β˜ρ = βρt0, γ˜ρ = γρT0, η˜P =
ηPL
2
DP
,
β˜P =
βPL
2
DP
, η˜T =
ηTL
2
DT
, β˜T =
βTL
2
DT
, α˜P =
αPL
DPP0
,
α˜T =
αTL
DTT0
, σ˜P =
σPL
DP
, σ˜T =
σTL
DT
, P˜M =
PM
P0
, T˜M =
TM
T0
.
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Dropping tildes for clarity, the corresponding dimensionless model equations, boundary con-
ditions and initial conditions are:
∂m
∂t
=
∂
∂x
[
(1−m− ρ) ∂
∂x
[
m (Λ + ρψ)
] ]
+ rmm (1−m− ρ)
[
1 +
AmP
cm + P
]
− βmm,
(39)
∂ρ
∂t
= rsm (1−m− ρ)
[
1 +
AsT
cs + T
]
− rdmρ
[
1 +
AdP
(cd + P ) (1 + γdT )
]
− βρρ (1−m− ρ)
[
1 + ε γρT
1 + γρT
]
,
(40)
∂
∂x
[
(1−m− ρ) ∂P
∂x
]
= ηPmP (1−m− ρ) + βPP (1−m− ρ) , (41)
∂
∂x
[
(1−m− ρ) ∂T
∂x
]
= ηTmT (1−m− ρ) + βTT (1−m− ρ) , (42)
∂
∂x
[
m (Λ + ρψ)
]
= 0 at x = 0,
∂
∂x
[
m (Λ + ρψ)
]
=
dΛ
dP
mM
∂P
∂x
at x = L, (43)
∂P
∂x
= −αP at x = 0, ∂P
∂x
= σP (PM − P ) at x = L, (44)
∂T
∂x
= −αT at x = 0, ∂T
∂x
= σT (TM − T ) at x = L, (45)
m (x, 0) = mi, (46)
ρ (x, 0) = ρi, (47)
wherein Λ(P ) =
χP
1 + (κP )nP
and ψ (m, ρ) = −χρ + δm
nρ
(1−m− ρ)nρ .
2.6 Model Parameterisation
A summary of the base case parameter values is provided in Table 1. Our parameter selec-
tions have mostly been informed by data and observations from relevant in vitro and in vivo
experimental studies. When appropriate data could not be found, we have chosen values
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that ensure biologically realistic results. Several important parameters (e.g. Am, cm, χP , κ,
nP ) have been assigned values that are dimensionally the same (or very similar) to those in
our earlier model of cap formation. We provided detailed justifications for these parameter
values in Watson et al. (2018), so below we focus on explaining the parameter selections that
are unique to the current study.
In vivo studies in the ApoE-deficient mouse have shown that plaque fibrous caps typi-
cally form over the course of several months (Kozaki et al., 2002). We therefore assume a
characteristic timescale of approximately 1 month and set t0 = 2.5× 106 s. For the domain
length, we set L = 120 µm. This value is based on data from Reifenberg et al. (2012), who
measured intimal thickness in the diseased aortic arches of mice around the time of initial
plaque SMC infiltration. For PDGF and TGF-β, we assume the characteristic concentrations
P0 = 10 ng ml
−1 and T0 = 1 ng ml−1. These values reflect reported concentrations of PDGF
in platelets (15–50 ng ml−1; Huang et al. (1988)) and TGF-β in blood plasma (2–12 ng ml−1;
Wakefield et al. (1995)).
In a detailed model of the fibroblast response to PDGF in dermal wound healing, Haugh
(2006) estimated PDGF diffusion coefficient and decay rate values that suggest a PDGF dif-
fusion distance of approximately 300 µm. Based on these estimates, we set our dimensionless
PDGF decay rate to be βP = 0.2. As TGF-β has an almost identical molecular weight to
PDGF, we expect that TGF-β will diffuse at a similar rate to PDGF in the plaque tissue.
However, active TGF-β has been reported to decay around two orders of magnitude faster
than PDGF (Wakefield et al., 1990), and we therefore set βT = 20. The other parameters
that determine the plaque growth factor profiles are more difficult to estimate. We assume,
for consistency, that σP = σT and we choose corresponding values for αP and αT that give
reasonable growth factor concentration ranges in the intima. The response of the model to
changes in the values of αP and αT will be an important focus of our numerical simulation
studies in Section 3.2. Note that we also set PM = TM = 0 because neither growth factor is
known to have a prominent source in the medial tissue.
ECM remodelling in the model is governed by a range of concentration-dependent stim-
ulatory and inhibitory effects of PDGF and TGF-β. The parameter values in these rela-
tionships have all been informed by data from in vitro experiments. Kubota et al. (2003)
used SMCs derived from human atherosclerotic plaques to show that TGF-β can increase
baseline collagen synthesis up to 2-fold, with a half-maximal response occurring for a TGF-β
concentration in the interval 0.2–0.5 ng ml−1. We therefore set As = 1 and cs = 0.35. Values
for ε and γρ are based on results from Vaday et al. (2001), who studied the impact of TGF-β
on tumour necrosis factor (TNF)-α-induced expression of MMP-9 in monocytes. Note that
TNF-α is known to be an important inflammatory cytokine in atherosclerosis progression
(Urschel and Cicha, 2015). Vaday et al. (2001) showed that, in the presence of 1 ng ml−1
TNF-α, MMP-9 activity decreased with increasing TGF-β concentration and was reduced by
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Parameter Description Dimensionless Reference
value
nP Exponent in SMC phase extra pressure function Λ 1.8 Schachter (1997)
κ Reciprocal of reference PDGF concentration in SMC phase extra
pressure function Λ
5.5 Schachter (1997)
χP Baseline SMC phase motility coefficient 1.75 Cai et al. (2007)
nρ Exponent in SMC phase extra pressure function ψ 2
δ SMC phase repulsion coefficient 0.45
χρ SMC phase affinity for ECM phase 0.3
rm Baseline rate of SMC phase proliferation 0.25 Breton et al. (1986)
Chappell et al. (2016)
Am Maximal factor of PDGF-stimulated increase in rate of SMC pro-
liferation
14 Munro et al. (1994)
cm PDGF concentration for half-maximal increase in rate of SMC
proliferation
1.5 Munro et al. (1994)
βm Rate of SMC phase loss 0.6 Lutgens et al. (1999)
rs Baseline rate of ECM phase synthesis by SMCs 1.8 Reifenberg et al. (2012)
As Maximal factor of TGF-β-stimulated increase in rate of ECM syn-
thesis
1 Kubota et al. (2003)
cs TGF-β concentration for half-maximal increase in rate of ECM
synthesis
0.3 Kubota et al. (2003)
rd Baseline rate of ECM phase degradation by SMCs 1.5
Ad Maximal factor of PDGF-stimulated increase in rate of ECM
degradation by SMCs
4 Borrelli et al. (2006)
cd PDGF concentration for half-maximal increase in rate of ECM
degradation by SMCs
2.5 Borrelli et al. (2006)
γd Reciprocal of reference TGF-β concentration for inhibition of
PDGF-stimulated ECM degradation by SMCs
0.5 Borrelli et al. (2006)
βρ Baseline rate of ECM phase degradation by immune cells 0.75
ε Maximal factor of TGF-β-stimulated decrease in rate of ECM
degradation by immune cells
0.25 Vaday et al. (2001)
γρ Reciprocal of reference TGF-β concentration for inhibition of
ECM degradation by immune cells
10 Vaday et al. (2001)
ηP Rate of PDGF uptake by SMC phase 2.5
βP Rate of PDGF decay 0.2 Haugh (2006)
ηT Rate of TGF-β uptake by SMC phase 2.5
βT Rate of TGF-β decay 20 Wakefield et al. (1990)
mM Volume fraction of synthetic SMCs in media 0.01
αP Rate of PDGF influx from endothelium 0.7
σP Permeability of IEL to PDGF 4
PM PDGF concentration in media 0
αT Rate of TGF-β influx from endothelium 2.5
σT Permeability of IEL to TGF-β 4
TM TGF-β concentration in media 0
mi Initial SMC volume fraction in intima 10
−4 Bennett et al. (2016)
ρi Initial ECM volume fraction in intima 0.02 Reifenberg et al. (2012)
Table 1: Base case parameter values. The final column reports any references that have
been used to calculate individual parameter values. Values that do not have references have
been chosen to ensure biologically reasonable results. Unless otherwise stated, all reported
simulations use these values.
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around 50–75% for TGF-β concentrations in the range 0.1–1 ng ml−1. We therefore estimate
ε = 0.25 and γρ = 10. The parameter values that quantify the competing effects of PDGF
and TGF-β on ECM remodelling by SMCs have been calculated using data from Borrelli
et al. (2006). Borrelli et al. (2006) showed that SMCs demonstrate very similar qualitative
patterns of MMP-2 and MMP-9 release in the presence of varying concentrations of PDGF
and TGF-β. We therefore base our quantitative estimates on the averaged responses of these
two MMPs to PDGF and TGF-β. In the absence of TGF-β, the data suggest an average
2.5-fold increase in basal MMP release at 20 ng ml−1 PDGF and an average 4-fold increase
at 50 ng ml−1 PDGF. When 5 ng ml−1 TGF-β is introduced at 50 ng ml−1 PDGF, the release
of MMPs is cut, on average, by around 50%. Based on these observations, we select Ad = 4,
cd = 2.5 and γd = 0.5.
Of course, the parameters discussed above determine only how ECM remodelling is mod-
ified in the presence of growth factors. The underlying baseline rates of ECM synthesis and
degradation (rs, rd and βρ) must be determined separately. It is difficult to ascertain typical
values for these parameters during in vivo plaque progression, so we base our parameter
selections on the following considerations. First, we assume that, as invasive plaque SMCs
undertake a process of continual ECM remodelling, the values of rs and rd should be of a
similar order. Furthermore, we assume that the value of rs must be sufficiently large to
allow plaque collagen to accumulate on a timescale similar to that reported in Reifenberg
et al. (2012). Second, we assume that the value of βρ should be smaller than the value of
rd. We make this assumption because, while inflammatory cells such as macrophages may
degrade the plaque ECM more aggressively than SMCs, these cells make up only a fraction
of the content of the generic tissue phase. Based on these assumptions, we estimate rs = 1.8,
rd = 1.5 and βρ = 0.75.
In Watson et al. (2018), we assumed a dimensionless baseline SMC proliferation rate
rm = 0.02. This value was estimated based on previous experimental observations that
suggested a proliferative index of around 1% for plaque SMCs (i.e. 1% of plaque SMCs
displaying evidence of mitotic activity at a given point in time). However, as discussed in
Section 1, recent SMC lineage tracing studies have indicated that plaque SMC proliferation
may be more prominent than previously appreciated. For example, Chappell et al. (2016)
have recently reported a plaque SMC proliferative index of approximately 4%. Furthermore,
this value was determined at an advanced stage of plaque progression, where a significant
SMC population had already assembled. Hence, accounting for likely effects such as cell-
cell and cell-ECM contact inhibition, we anticipate that the plaque SMC proliferative index
could be even larger in early cap formation. We therefore assume a significant increase in
our previous estimate and set rm = 0.25. To our knowledge, no recent lineage tracing study
has reported an equivalent calculation for the SMC apoptotic index. Hence, for the SMC
death rate in the model, we use the apoptotic index of 1% that was calculated by Lutgens
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et al. (1999) and set βm = 0.6. This value corresponds to a typical SMC apoptosis time of
approximately 8 hours.
Finally, we briefly comment on the rationale for our parameterisation of the SMC affinity
for the ECM phase χρ. Expansion of the flux term in equation (39) shows that χρ represents
an effective haptotaxis coefficient for SMC movement up gradients in the collagen-rich ECM.
The extent to which haptotactic SMC migration contributes to in vivo cap formation is not
well known. We therefore make a conservative initial estimate of χρ = 0.3 and will investigate
the sensitivity of the model to changes in this value in Section 3.2. Note that this conservative
estimate for χρ also arises due to practical considerations. Numerical simulations indicate
that the model can become ill-posed if the value of χρ is chosen to be too large. This issue
appears to be related to the onset of negative SMC diffusion, which is an occurrence that
we envisage to be unlikely during in vivo plaque growth. We therefore avoid such parameter
regimes in the simulations that are presented in this paper. In Section 4, we will discuss this
issue in greater detail and propose amendments that can be made to the model to reduce or
eliminate the ill-posed region of the parameter space.
3 Results
Before presenting numerical solutions of the model system (39)–(47), we begin this section by
performing a simplified steady state analysis that provides useful insight into the relationship
between the SMC phase and the collagenous ECM phase in the model plaque.
3.1 Analytical Results
The mathematical model derived in Section 2 provides a significant challenge for analytical
studies. Indeed, given the highly nonlinear nature of the model equations, it seems very
unlikely that closed-form expressions could be derived for any spatially inhomogeneous steady
state solutions. Worthwhile progress can be made, however, if we exploit the absence of a
flux term in the ECM equation and investigate the steady state ECM phase solution at a
fixed spatial position for fixed values of the other model variables. This analysis, which
we will use to interpret the numerical results in Section 3.2, allows us to understand why
a particular combination of steady state values for P , T and m correspond to a particular
steady state value for ρ at a given location in the plaque.
Consider a fixed point inside the model domain, and let us assume that, at that point, the
PDGF and TGF-β concentrations take the fixed (steady state) values P ∗ and T ∗. Assuming
that the SMC volume fraction has the fixed (steady state) value m∗ at the same point,
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equation (40) gives the following expression for the steady state ECM volume fraction ρ∗:
Rsm
∗ (1−m∗ − ρ∗)−Rdm∗ρ∗ −Bρρ∗ (1−m∗ − ρ∗) = 0, (48)
where ρ∗ + m∗ < 1. Note that, in the above expression, we have introduced the positive
constants Rs (T
∗) = rs
[
1 + AsT
∗
cs+T ∗
]
, Rd (P
∗, T ∗) = rd
[
1 + AdP
∗
(cd+P ∗)(1+γdT ∗)
]
, and Bρ (T
∗) =
βρ
[
1+ε γρT ∗
1+γρT ∗
]
. These constants represent the (local) steady state rates of ECM synthesis by
SMCs, ECM degradation by SMCs, and ECM degradation by immune cells, respectively.
Rearranging equation (48) gives the following quadratic in ρ∗:
ρ∗2 +
[
m∗
(
1− Rs
Bρ
− Rd
Bρ
)
− 1
]
ρ∗ +
Rs
Bρ
m∗ (1−m∗) = 0. (49)
Setting µ (T ∗) = Rs
Bρ
and λ (P ∗, T ∗) = Rd
Bρ
, this quadratic gives two possible solutions ρ∗± for
the steady state ECM volume fraction in terms of m∗:
ρ∗± (m
∗) =
1
2
[
1−m∗ (1− µ− λ) ±
√[
1−m∗ (1− µ− λ)
]2
− 4µm∗ (1−m∗)
]
, (50)
where 0 < m∗ < 1. It is trivial to show that the discriminant of equation (50) is strictly
positive and, hence, that the two solutions are real-valued, positive and distinct. However, for
either solution to be physically meaningful, it must satisfy the condition 0 < ρ∗± < 1 −m∗.
It can therefore be shown that ρ∗− gives the only admissable steady state solution and,
furthermore, that this steady state is always stable. From here, we drop the subscript on ρ∗−
and use ρ∗ to refer to the negative root in equation (50).
For fixed values of µ and λ, plots of ρ∗ (m∗) for m ∈ (0, 1) demonstrate a biphasic
behaviour where ρ∗ initially increases from zero with increasing m∗ but then diminishes back
towards zero as m∗ approaches one. The region of decreasing ρ∗ is attributable to the fact
that as m∗ increases, ECM synthesis is increasingly inhibited by the reduced availability of
generic tissue material. An interesting consequence of this biphasic relationship between ρ∗
and m∗ is that, for each pair of growth factor concentrations P ∗ and T ∗ (or parameter values
µ and λ), there exists a SMC volume fraction m̂∗ that produces a maximum steady state
ECM volume fraction ρ̂ ∗. Therefore, in what follows, we shall derive expressions for both
m̂∗ and ρ̂ ∗, and use these expressions to explore the conditions that lead to optimal ECM
deposition at a given point in the plaque.
We begin by looking for stationary points of the function ρ∗ (m∗), whose first derivative
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is given by the following:
dρ∗
dm∗
=
1
2
µ+ λ− 1 + 1 + µ− λ−m∗
[
(1− µ− λ)2 + 4µ
]
√[
1−m∗ (1− µ− λ)
]2
− 4µm∗ (1−m∗)
 . (51)
Before proceeding, we remark that the second derivative of ρ∗ (m∗) is strictly negative and,
hence, that any stationary point found from equation (51) will indeed be a maximum. Setting
equation (51) equal to zero, rearranging terms and squaring leads to the following quadratic
equation in m̂∗: [
(1− µ− λ)2 + 4µ
]
m̂∗2 − 2 (1 + µ− λ) m̂∗ + 1− λ = 0, (52)
which has corresponding solutions:
m̂∗± =
1 + µ− λ ± √λ (1− µ− λ)
(1− µ− λ)2 + 4µ . (53)
The physically meaningful solution, which must satisfy the condition 0 < m̂∗± < 1, is again
given by the negative root. Selecting the negative root and dropping the subscript, it is
possible to show that m̂∗ can be written in the reduced form:
m̂∗ (µ, λ) =
1 +
√
λ
1 + µ+ λ+ 2
√
λ
, (54)
which, upon substitution into the negative root in equation (50), gives the corresponding
form of ρ̂ ∗:
ρ̂ ∗ (µ, λ) =
µ
1 + µ+ λ+ 2
√
λ
. (55)
The dependence of ρ̂ ∗ and m̂∗ on µ and λ can be inspected visually by plotting 2D
heatmaps of the right hand sides of equations (54) and (55). However, these plots have
limited utility for the interpretation of numerical simulation results because, at steady state
in a given simulation, the values of µ and λ at each location in the plaque are not immediately
obvious. This is because µ and λ depend not only on the local growth factor concentrations
P ∗ and T ∗, but also on the ten parameters (rs, As, cs, rd, Ad, cd, γd, βρ, ε, γρ) that appear in
the definitions of Rs, Rd and Bρ. Therefore, to support the interpretation of the numerical
results that will be presented in Section 3.2, we instead plot heatmaps of ρ̂ ∗ and m̂∗ as
functions of P ∗ and T ∗ where the above parameters have been assigned their base case
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(a) (b)
Figure 4: Heatmaps that show how (a) the maximum steady state ECM volume fraction ρ̂ ∗
and (b) the corresponding SMC volume fraction m̂∗ at a fixed point in the plaque vary with
the local growth factor concentrations P ∗ and T ∗ for (P ∗, T ∗) ∈ [0, 1]× [0, 1]. Note that the
parameters that appear in the definitions of ρ̂ ∗ and m̂∗ (rs, As, cs, rd, Ad, cd, γd, βρ, ε, γρ)
have been assigned their base case values (see Table 1). Explicit expressions for ρ̂ ∗ (P ∗, T ∗)
and m̂∗ (P ∗, T ∗) are not provided but can be inferred from the expressions in equations (54)
and (55), and the definitions in the text after equations (48) and (49).
values (Figure 4). Note that expressions for ρ̂ ∗ (P ∗, T ∗) and m̂∗ (P ∗, T ∗) can be written
down explicitly (see the relevant definitions above), but we omit these here for brevity.
Figures 4a and 4b present respective plots of ρ̂ ∗ (P ∗, T ∗) and m̂∗ (P ∗, T ∗) for (P ∗, T ∗) ∈
[0, 1]× [0, 1]. These intervals for P ∗ and T ∗ reflect the typical ranges of dimensionless growth
factor concentrations that will be considered in our numerical simulations in Section 3.2.
Recall that, for each parameter combination (P ∗, T ∗), these heatmaps indicate the maximum
steady state ECM volume fraction that could be reached at a fixed point in the plaque
(Figure 4a), and the local SMC volume fraction that is required to achieve this maximum
(Figure 4b). For SMC volume fractions that are either above or below those plotted for each
(P ∗, T ∗) in Figure 4b, the corresponding steady state ECM volume fractions will be smaller
than those plotted in Figure 4a. Intuitively, ρ̂ ∗ takes its largest values when T ∗ is large
and P ∗ is small (i.e. high net rate of ECM synthesis and low net rate of ECM degradation),
and its smallest values when T ∗ is small and P ∗ is large (i.e. low net rate of ECM synthesis
and high net rate of ECM degradation). The corresponding behaviour of m̂∗, on the other
hand, is less intuitive. Figure 4b indicates that, over the majority of the plotted (P ∗, T ∗)
parameter space, the maximum ECM volume fraction can be generated by a relatively small
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volume fraction (0.1–0.2) of SMCs.
Figure 4a indicates that, while both growth factors can have a significant impact on plaque
ECM levels, ρ̂ ∗ is much more sensitive to T ∗ than to P ∗ over the relevant concentration range.
This is because TGF-β plays a role not just in synthesising the collagenous ECM, but also
in preventing its degradation. To quantify the relative sensitivity to T ∗ and P ∗, we note
that, in general, an increase in T ∗ from zero to one causes ρ̂ ∗ to increase by approximately
0.2, while a similar change in P ∗ causes ρ̂ ∗ to decrease by approximately 0.1. Of course, it is
also important to consider the SMC levels that are required to attain these maximum ECM
volume fractions at different plaque growth factor levels. For T ∗ close to zero, Figure 4b
indicates that an SMC volume fraction of around 25–30% is required to maximise the steady
state ECM volume fraction at around 20–30%. However, for T ∗ close to one, a maximum
steady state ECM volume fraction of 40–50% can be generated by an SMC volume fraction
of less than 15%. The model therefore suggests that, in the presence of favourable TGF-β
levels, it is possible to synthesise around twice as much collagenous ECM with about half as
many tissue-synthesising SMCs.
The above results provide a useful tool with which to interpret the final outcome of cap
formation in a given model simulation. However, it is also important to emphasise that this
simplified analysis does not allow us to readily predict cap formation efficacy in a particular
case. We have focussed on a fixed spatial position in the plaque and have disregarded
dynamic interactions between the various model variables, including the role of PDGF in
SMC recruitment and the mechanical feedback between the SMCs and the ECM that they
deposit. In the next section, we investigate the importance of these factors, and others, by
performing numerical simulations with the full system of model equations.
3.2 Numerical Results
We begin this section by presenting results from a simulation with the base case param-
eter values. This is followed by a sensitivity analysis that investigates the impact of key
parameters on cap formation. All numerical solutions have been obtained by discretising
equations (39)–(45) in space and/or time using a central differencing scheme for P and T ,
the trapezoidal rule for ρ, and the Crank-Nicolson method for m. The resulting systems of
nonlinear equations were solved sequentially for each variable at each timestep by iteration.
3.2.1 Base Case Simulation
We initiate the base case simulation by prescribing small and spatially uniform volume
fractions for m and ρ in the plaque. The initial profiles are presented in Figure 5 alongside
approximate initial solutions for the plaque growth factor concentrations P and T . By using
the fact that 1 −m − ρ = const and m ≈ 0 at t = 0, the P and T profiles represent exact
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Figure 5: Initial conditions for each of the model variables in the base case simulation. The
PDGF concentration is shown in blue, the TGF-β concentration in green, the ECM volume
fraction in magenta, and the SMC volume fraction in red.
solutions of simplified forms of equations (41) and (42) (i.e. ∂
2G
∂x2
= βGG, for G = P, T ),
subject to the corresponding boundary conditions (44) and (45). An important feature to
note about the initial growth factor profiles is the distinct difference between the distributions
of endothelium-derived PDGF and TGF-β. The PDGF profile, which is diffusion-dominated
(βP  1), shows an approximately linear decrease across the intima, while TGF-β, which is
degradation-dominated (βT  1), shows a rapid exponential decline. Consequently, TGF-
β is more strongly localised to the endothelium and, of course, to the desired region of
collagenous cap formation.
The time evolution of the model variables in the base case simulation is presented in
Figure 6 (note that the time points for the ECM phase plots in Figure 6b do not correspond
exactly to those for the plots of the other variables). The results demonstrate significant
accumulations of SMCs (Figure 6a) and ECM in the cap region over the course of the
simulation and a concurrent reduction in the overall concentrations of PDGF (Figure 6c)
and TGF-β (Figure 6d). The reduction in plaque PDGF and TGF-β levels is partly due to
uptake by the invading SMCs, but can mostly be attributed to reduced chemical diffusion
through the increasingly populated cap region. Note that the PDGF profile undergoes a more
dramatic change than the TGF-β profile as a consequence of this modulated diffusivity.
Figure 6a shows that the media-derived model SMCs respond to the diffusible PDGF sig-
nal by migrating towards the endothelium and proliferating rapidly over the first 2 months of
simulation time. Due to the ongoing increase in ECM deposition and concurrent reduction
in PDGF levels, the SMCs divide more slowly after this time point and the plaque SMC
population peaks at around 4 months. Interestingly, Figure 6b demonstrates that cap for-
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Figure 6: (a) SMC volume fraction, (b) ECM volume fraction, (c) PDGF concentration
and (d) TGF-β concentration profiles in the plaque at several times during the base case
simulation. Arrows indicate the direction of sequential time points, which correspond to
t = 1.3, 2.0, 2.7 and 6.0 for the ECM phase and t = 0.8, 1.5, 2.0 and 4.0 for the other
variables. Data at the time point t = 2.0 has been emboldened on each plot.
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mation occurs on a longer timescale than that required for the ECM-synthesising SMCs to
accumulate. After 2 months of simulation time, only 50% of the final ECM content has been
deposited, and the approximate steady state ECM profile is not attained until after about 6
months. The results in Figures 6a and 6b are qualitatively and quantitatively consistent with
the experimental observations of Reifenberg et al. (2012). For ApoE knockout mice fed a
high-fat diet for 24 weeks, Reifenberg et al. (2012) found that plaque SMC content increased
from around 3% at 8 weeks to around 7% at both 16 and 24 weeks, while plaque collagen
content increased from around 3% at 8 weeks to around 17% at 16 weeks and then to around
24% at 24 weeks. These values show evidence of an early saturation in SMC numbers and
a delayed saturation in collagen levels, both of which occur on similar timescales to those
depicted in our simulation data.
Figure 7 presents the profile of each model variable in the plaque at the later time t = 8
(solid lines). The simulation is close to steady state at this time point, and the only notable
change from the results at the latest time points in Figure 5 is a small reduction in the SMC
volume fraction throughout the domain. This reduction in SMC numbers appears to be due
to the delayed accumulation of ECM, which causes increased inhibition of SMC migration
and SMC proliferation at a late stage of cap formation. At t = 8, the total volume fractions of
SMCs and collagenous ECM in the plaque are approximately 8.6% and 21.4%, respectively.
These values are consistent with observations from several studies of plaque growth in the
ApoE knockout mouse (Mallat et al., 2001; Clarke et al., 2006; Reifenberg et al., 2012).
In Figure 7, we have also plotted the values of m̂∗ and ρ̂ ∗ at each spatial position in
the plaque (dotted lines). These plots, which have been constructed using equations (54)
and (55), represent the maximum ECM volume fraction (ρ̂ ∗) that could be attained at each
position x, and the corresponding SMC volume fraction (m̂∗) that would be required to
achieve this maximum. For each x, the values of m̂∗ and ρ̂ ∗ are given by a unique pair of
values µ and λ, which depend on the local PDGF and TGF-β concentration values P (x, 8)
and T (x, 8). The m̂∗ and ρ̂ ∗ curves show that, in the majority of the plaque tissue (x & 0.08),
the simulated SMC phase volume fraction m (x, 8) is below the level required to maximise
ECM deposition. For x . 0.08, the extent of ECM deposition is again sub-optimal, but,
in this case, the reduced ECM volume fraction ρ (x, 8) is the result of over -recruitment
of SMCs. Interestingly, Figure 7 shows that the simulated ECM volume fraction remains
relatively close to maximal levels throughout the region proximal to the endothelium (i.e.
x . 0.2). This is despite the fact that the simulated SMC volume fraction is considerably
larger than m̂∗ for x ≈ 0 and considerably smaller than m̂∗ for x ≈ 0.2.
Figure 8 presents additional data that helps to explain why near-maximal ECM de-
position can be attained for a wide range of SMC volume fractions near the endothe-
lium in the base case simulation. For a series of spatial positions in the model plaque
(x = 0, 0.1, 0.2, 0.3, 0.45, 1), Figure 8 plots the analytical expression for the steady state
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Figure 7: Base case simulation results that show approximate steady state profiles (solid
lines) for the PDGF concentration (blue), TGF-β concentration (green), ECM volume frac-
tion (magenta) and SMC volume fraction (red). Dotted lines represent the analytically-
derived maximum steady state ECM volume fraction ρ̂ ∗ (pink) and corresponding steady
state SMC volume fraction m̂∗ (red) at each x. The m̂∗ and ρ̂ ∗ values are functions of the
local PDGF and TGF-β concentrations and have been calculated at each x by equations (54)
and (55), respectively. All plots taken at time t = 8.
ECM volume fraction ρ∗ (m∗) (negative root in equation (50); solid lines). Each individual
ρ∗ (m∗) curve again uses the corresponding local growth factor concentrations P (x, 8) and
T (x, 8). In addition to these curves, we plot individual data points that show the simulated
(m, ρ) values at each x at t = 8 (open circles), and the maximum (m̂∗, ρ̂ ∗) of each individual
ρ∗ (m∗) curve (asterisks). Note, firstly, that the simulated (m, ρ) data points are all strongly
aligned with their corresponding ρ∗ (m∗) curves. This confirms that, at t = 8, the base case
simulation is indeed very close to steady state. Each individual ρ∗ (m∗) curve in Figure 8 has
a unique shape and a unique maximum value, but all of the plots share similar qualitative
features. In particular, each curve is relatively flat for a wide range of m∗ values either side
of its maximum at m̂∗. Therefore, when the simulated steady state value of m lies inside
the shallow region of the ρ∗ (m∗) curve — as is the case near the endothelium in the base
case simulation — the simulated steady state value of ρ will differ only slightly from its
theoretical maximum. At x = 0 in the base case simulation, for example, the analytical
results give ρ̂ ∗ ≈ 0.415 and corresponding m̂∗ ≈ 0.155. The simulated SMC volume fraction
at x = 0 for t = 8 is much larger (m ≈ 0.202) than m̂∗, but the corresponding simulated
ECM volume fraction (ρ ≈ 0.408) remains very close to ρ̂ ∗. Indeed, Figure 8 indicates that,
at x = 0, any simulated steady state m in the range [0.102, 0.233] would give a steady state
ρ > 0.4 for the same local growth factor concentrations. This suggests that the fibrous cap
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Figure 8: Plot that compares near-steady state m and ρ values for several values of x in
the base case simulation with the corresponding analytical steady state results derived in
Section 3.1. Solid lines represent the expressions ρ∗ (m∗) (negative root in equation (50))
at each of the spatial positions x = 0 (red), x = 0.1 (green), x = 0.2 (blue), x = 0.3
(magenta), x = 0.45 (orange) and x = 1 (purple). Each ρ∗ (m∗) curve is a function of the
local PDGF and TGF-β concentrations. Individual data points represent the near-steady
state (m, ρ) values from the base case simulation (open circles) and the maximum (m̂∗, ρ̂ ∗)
of each individual ρ∗ (m∗) curve (asterisks) at each x. All curves and data points taken at
time t = 8.
generated in the base case simulation would be robust to a relatively large reduction in cap
region SMC numbers.
3.2.2 Sensitivity Analysis
The base case simulation results demonstrate how SMCs can accumulate in the plaque and
synthesise a collagenous cap in response to diffusible signals from endothelium-derived PDGF
and TGF-β. In this section, we perform additional sensitivity analyses to investigate how the
values of certain parameters determine the extent of collagen deposition in the cap region.
In particular, we investigate both the impact of SMC adhesion to the nascent collagenous
matrix and the role of the relative rates of growth factor influx into the plaque.
SMC Affinity for Collagen
In vitro studies have demonstrated that vascular SMCs can elicit a strong haptotactic re-
sponse to types I, IV and VIII collagen (Nelson et al., 1996; Hou et al., 2000). The extent of
any haptotactic contribution to SMC migration during in vivo cap formation is unclear, but,
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since plaque ECM is known to contain both collagen I and collagen VIII (Adiguzel et al.,
2009), it seems plausible that SMC haptotaxis may play an important role. We investigate
this possibility below by examining the sensitivity of the model to the parameter χρ, which
quantifies the affinity of the plaque SMCs for the collagenous ECM phase.
We find that setting χρ = 0 produces results that are only marginally different to those
from the base case simulation. This highlights that our choice of χρ = 0.3 for the base case
value was particularly conservative, and we therefore consider the impact of a significant
increase in this value. For a sensitivity simulation with χρ = 0.8, we find that the solution
dynamics are practically identical to the base case simulation for the first 5–6 weeks of sim-
ulation time. Beyond this point, however, the emerging ECM phase exerts and increasing
influence on the SMC behaviour and the model solution for larger χρ diverges from the base
case simulation dynamics. Figure 9 compares the approximate steady state SMC and ECM
profiles from the base case simulation and from the case with χρ = 0.8. As would be ex-
pected, the increase in χρ results in increased recruitment of SMCs to the region proximal
to the endothelium. More surprising, however, is that the overall plaque SMC content is
reduced from 8.6% to 7.1%, and that there is no overall increase in ECM deposition in the
cap region. The reduction in SMC numbers appears to be due to an increased squeeze on the
PDGF influx from the endothelium, which reduces both SMC recruitment from the media
and SMC mitosis inside the intima. The lack of increase in cap ECM deposition, on the
other hand, can be attributed to the fact that the SMC volume fraction near the endothe-
lium has increased well beyond the level required to maximise ECM synthesis (c.f. Figure 4).
Of course, a potential benefit of the increased haptotaxis simulated here is that less ECM is
deposited beyond the cap region (due to the drop in SMC numbers), which may contribute
to a reduction in the overall hardening of the diseased arterial tissue.
Growth Factor Influx
A key target of this study has been to understand how plaque SMC behaviour and fibrous
cap formation are regulated by the growth factors PDGF and TGF-β. Since it is difficult
to quantify the concentrations of these chemicals in a given in vivo plaque, we perform a
range of sensitivity analyses below to investigate how the relative rates of PDGF and TGF-β
influx from the endothelium can contribute to the density, and therefore the stability, of the
collagenous cap. We first examine the consequences of varying the growth factor influx rates
αT and αP independently, before considering the impact of varying them simultaneously.
To facilitate the comparison of cap formation dynamics in the simulations that we perform
in this section, we introduce a simple metric to measure the SMC and ECM levels proximal
to the endothelium at a given point in time. Specifically, we define the quantity Vi (t;X),
which denotes the average volume fraction of phase i (i = m, ρ) in the interval x ∈ [0, X] at
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Figure 9: Approximate steady state SMC volume fraction (red lines) and ECM volume
fraction (magenta lines) profiles in the plaque for the base case simulation (solid lines) and
a simulation with increased SMC affinity for the ECM phase (χρ = 0.8; dashed lines). All
plots taken at time t = 8.
time t:
Vi (t;X) =
1
X
∫ X
0
i (x, t) dx, (56)
where 0 < X  1. In all that follows, we choose (arbitrarily) to set X = 0.2 and assume
that the spatial interval x ∈ [0, 0.2] represents what we shall refer to as the cap region. We
remark that we have calculated Vi values for several different choices of the cap region width,
but (within reasonable bounds) the precise choice of X does not alter our qualitative findings
in any of the below sensitivity studies.
Figure 10 presents the approximate steady state SMC and ECM profiles for a simulation
with no influx of TGF-β (i.e. αT = 0). This scenario mimics the experimental set-ups
used by Mallat et al. (2001) and Lutgens et al. (2002), both of whom studied the impact
of blocking TGF-β signalling during plaque growth in the ApoE knockout mouse. The
results show that the absence of TGF-β has reduced the total collagen deposition in the
plaque by approximately 15%. This is a smaller reduction in collagen deposition than may
have been expected, but it is clear that collagen levels have been rescued to some degree
by a corresponding increase in SMC numbers. Indeed, this increase in SMC numbers is
directly attributable to the reduced rate of collagen deposition because contact inhibition of
SMC proliferation remains lower, and PDGF influx from the endothelium remains higher,
throughout the simulation. Having said that, the simulation results still demonstrate that
the absence of TGF-β can decimate the fibrous cap. Figure 10 shows that, near steady state,
the average ECM volume fraction in the cap region Vρ (t; 0.2) has decreased by approximately
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Figure 10: Approximate steady state SMC volume fraction (red lines) and ECM volume
fraction (magenta lines) profiles in the plaque for the base case simulation (solid lines) and
a simulation with no influx of TGF-β (αT = 0; dashed lines). All plots taken at time t = 8.
40% from 0.381 to 0.235. This result is consistent with the findings of Mallat et al. (2001)
and Lutgens et al. (2002), who report that inhibition of TGF-β signalling can lead to an
unstable plaque phenotype.
For PDGF, we cannot simulate a case where chemical signalling is blocked entirely be-
cause cap formation in the model is reliant upon PDGF-stimulated recruitment of SMCs from
the media. The model does, however, elicit interesting dynamics over a range of non-zero
values of αP , and we therefore consider the impact of both an increase and a decrease in this
parameter. Figure 11 compares the initial PDGF profile from the base case simulation with
the initial PDGF profiles for αP = 0.3 and αP = 1.1. Note that increasing the value of αP
not only increases the PDGF gradient but also increases the PDGF concentration through-
out the plaque tissue. Figure 12 presents the corresponding SMC and ECM profiles for each
value of αP after 8 months of simulation time. The SMC profiles show a large disparity in
their volume fractions, which is particularly pronounced near the endothelium (Figure 12a).
This reflects the significant differences in the relative rates of PDGF-stimulated chemotaxis
and proliferation in each case. The ECM profiles, on the other hand, show relatively little
variation in their volume fractions, but do still demonstrate some interesting features (Fig-
ure 12b). For example, the case with larger αP produces a slightly lower cap collagen content
compared to the base case simulation despite recruiting over 60% more SMCs to the cap
region. This result can mostly be attributed to the fact that the cap SMC volume fraction
has significantly exceeded the level required to attain optimum ECM synthesis. However,
note that the elevated plaque PDGF levels also contribute to an enhanced rate of ECM
degradation by increasing MMP production by the invading SMCs. In contrast, in the sim-
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Figure 11: Initial PDGF concentration profiles in the plaque for the base case simulation
(solid line), a simulation with a smaller rate of PDGF influx from the endothelium (αP = 0.3;
dot-dash line) and a simulation with a larger rate of PDGF influx from the endothelium
(αP = 1.1; dashed line).
ulation with smaller αP , the sparse SMC population makes a remarkably strong attempt at
cap synthesis. In this case, the collagen content in the cap region is only 20% less than that
in the base case simulation despite a cap SMC content that has been depleted by over 60%.
Of course, if we examine these SMC and ECM profiles at only one time point, we get
no real indication of the overall simulation dynamics. Hence, in Figure 13, we also present
the average cap SMC volume fraction Vm (t; 0.2) and the average cap ECM volume fraction
Vρ (t; 0.2) as functions of time t. For αP = 1.1, Figure 13a shows a slow initial rate of cap
SMC recruitment, followed by a period of rapid population growth that saturates after 3–4
months. However, despite a cap SMC population that significantly exceeds the base case
levels from 2 months onwards, the temporal accumulation of cap ECM shows a very similar
pattern to the base case simulation and fails to exceed the base case value of Vρ at any
time (Figure 13b). For αP = 0.3, however, we observe completely different cap formation
dynamics. The reduced PDGF levels in this case inhibit both the rate and the extent of cap
SMC recruitment (Figure 13a), which, in turn, creates a significant lag in the rate of cap
ECM accumulation (Figure 13b). Hence, although these SMCs clearly have the capacity to
generate large quantities of ECM, their limited numbers ensure that this process takes an
extended period of time.
We conclude this study by briefly considering the consequences of simultaneously chang-
ing the rates of influx of both PDGF and TGF-β. Figure 14 presents bar charts of Vρ (t; 0.2)
and Vm (t; 0.2) at time t = 8 for simulations with a range of values of αT and αP . Specifically,
we report results for each unique pair of values from αT = 0, 1.25, 2.5, 3.75, 5 and αP =
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Figure 12: Approximate steady state (a) SMC volume fraction and (b) ECM volume fraction
profiles in the plaque for the base case simulation (solid lines), a simulation with a smaller
rate of PDGF influx from the endothelium (αP = 0.3; dot-dash lines) and a simulation with
a larger rate of PDGF influx from the endothelium (αP = 1.1; dashed lines). All plots taken
at time t = 8.
0 2 4 6 8
0
0.05
0.1
0.15
0.2
0.25
(a)
0 2 4 6 8
0
0.1
0.2
0.3
0.4
(b)
Figure 13: Plots that show how the average cap region volume fractions of (a) SMCs
Vm (t; 0.2) and (b) ECM Vρ (t; 0.2) vary with time for the base case simulation (solid lines),
a simulation with a smaller rate of PDGF influx from the endothelium (αP = 0.3; dot-dash
lines) and a simulation with a larger rate of PDGF influx from the endothelium (αP = 1.1;
dashed lines).
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Figure 14: Charts that show how the rates of PDGF influx αP and TGF-β influx αT influence
the average volume fractions of (a) SMCs Vm (t; 0.2) and (b) ECM Vρ (t; 0.2) in the cap region
after 8 months of simulation time. Individual simulations were performed for each unique
pair of values from the lists αP = 0.3, 0.5, 0.7, 0.9, 1.1 and αT = 0, 1.25, 2.5, 3.75, 5. The
central bar on each chart represents the outcome of the base case simulation.
0.3, 0.5, 0.7, 0.9, 1.1. Note that results from the base case simulation are represented by the
central bar on each chart. Figure 14a, which plots the Vm value for each simulation, shows
two clear trends: (1) increasing Vm with increasing αP (mainly due to increased SMC prolif-
eration) and (2) decreasing Vm with increasing αT (due to the inhibitory effects of increased
ECM deposition). Interestingly, the plot for Vρ indicates a relatively large region of the
(αT , αP ) parameter space where the model predicts a robust cap formation response (Fig-
ure 14b). This region corresponds to parameter regimes with large TGF-β levels, moderate
PDGF levels and, consequently, moderate volume fractions of cap SMCs.
4 Discussion
Mature atherosclerotic plaques contain a lipid-rich core of necrotic material and release of this
material into the circulation can cause myocardial infarction or stroke. Fibrous cap formation
provides protection against these outcomes by stabilising the plaque and sequestering the
dangerous plaque content from the bloodstream. However, the mechanisms that regulate cap
formation, and the factors that may subsequently lead the cap to fail, are poorly understood.
In this paper, we have developed a multiphase model to investigate collagenous cap synthesis
by growth factor-stimulated SMCs. The model includes representations of the growth factors
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PDGF and TGF-β, and we have used the model to study the co-operation (and competition)
between these diffusible chemicals in the recruitment of vascular SMCs to remodel the plaque
ECM.
4.1 Applicability of the model to human atherosclerosis
The model that we have developed in this study is designed to investigate cap formation
in the ApoE-deficient mouse. We have chosen to focus on this transgenic mouse model
of atherosclerosis because there exists an extensive experimental literature that we have
used to inform and validate our modelling assumptions. It would, of course, be possible to
extrapolate our model to human atherosclerosis by solving the equations on a domain of
significantly greater dimensional width (e.g. 1 mm). However, the behaviour of vascular
SMCs in human plaques remains poorly understood (Bennett et al., 2016). Unlike mice,
healthy human arteries contain a resident population of intimal SMCs and the extent of
medial SMC recruitment to human plaques has yet to be established.
4.2 Comparison with previous work and limitations of the model
The research presented in this paper has some similarities and several key differences to
the earlier approach of Watson et al. (2018). In Watson et al. (2018), we established a
novel modelling framework with non-standard boundary conditions to allow us to study
the chemotactic recruitment of plaque SMCs from the media in response to an influx of
endothelium-derived PDGF. We did not explicitly model the deposition of a fibrous cap.
Instead, we assumed that the plaque ECM profile would evolve to more-or-less reflect the
plaque SMC profile and, hence, that an increase in SMC recruitment to the cap region would
generally improve cap stability. The current work uses the modelling framework of Watson
et al. (2018) as a foundation, but builds a substantial new model that focusses on ECM
synthesis and degradation by plaque cells in response to an influx of both PDGF and TGF-β
from the endothelium. The new model also includes haptotactic SMC migration in response
to dynamically varying gradients in the ECM and, hence, to the best of our knowledge, this
paper presents the first attempt to include both chemotactic and haptotactic cell movement
in a multiphase model. The results that we have reported have demonstrated that the
plaque SMC profile does not necessarily provide a reliable indication of the corresponding
ECM profile, nor of the overall likelihood of fibrous cap stability. This is in contrast to the
assumptions that we made previously in the simpler model of Watson et al. (2018).
By retaining the modelling framework from our previous study, we have also retained
some of the limitations of the earlier approach. In particular, the model remains on a
fixed domain and does not explicitly account for the lipoprotein influx and the associated
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inflammatory response that may contribute to continued plaque growth during the process
of cap formation. The current work can therefore be interpreted as a model of cap formation
in a plaque that otherwise exists in a dynamic equilibrium (i.e. where any influx of LDL
and immune cells from the bloodstream is exactly balanced by an efflux of lipid-loaded
foam cells to the adventitial lymphatics). Of course, even with this interpretation of the
model, it is possible to argue that we should incorporate domain growth to account for
the accumulation of SMCs and collagenous ECM in the plaque. In the numerical results
presented in Section 3.2, for example, the total fraction of the plaque occupied by SMCs
and ECM increases over the course of a simulation by between 17–35% depending on the
choice of parameters. In the absence of domain growth, we assume that this increase in
the plaque SMC and ECM levels is balanced by an equivalent reduction in the volume
fraction of the generic tissue phase. This reduction in generic tissue phase material can be
interpreted as a loss of the initial non-collagenous ECM, which is degraded and subsequently
recycled, and as a loss of interstitial fluid, which is squeezed out of the plaque or absorbed
by SMCs to produce new material. We note, however, that this interpretation becomes less
reasonable if the total SMC and ECM volume fractions in the plaque become large because
significant quantities of other generic tissue phase constituents (e.g. immune cells, lipids) are
also effectively lost from the tissue during cap formation. Despite these limitations of the
approach, we believe that the fixed domain model provides a useful and computationally
straightforward approximation to the problem of modelling atherosclerotic cap growth. In
future studies, we will develop a comprehensive moving boundary approach to explore how
dynamic expansion of the intima by immune cell and SMC activity can influence the efficacy
of cap formation.
4.3 Analytical results explain the (local) SMC-ECM relationship
One of the key benefits of employing a fixed domain is that the model remains amenable
to mathematical analysis. In Section 3.1, we used the absence of a flux term in the ECM
phase equation to study the factors that determine the steady state ECM volume fraction
at a given position in the plaque. Specifically, we showed, for fixed concentrations of the
growth factors PDGF and TGF-β, that the steady state ECM volume fraction ρ∗ has a
biphasic dependence on the steady state SMC volume fraction m∗, and, correspondingly,
that there exists a steady state SMC volume fraction m̂∗ that gives a maximum steady
state ECM volume fraction ρ̂ ∗. Moreover, we derived simple expressions for m̂∗ and ρ̂ ∗ in
terms of the dimensionless parameter groupings µ and λ, where µ represents the ratio of the
net rate of ECM synthesis by SMCs to the net rate of ECM degradation by immune cells
and λ represents the ratio of the net rate of ECM degradation by SMCs to the net rate of
ECM degradation by immune cells. The most significant finding of this analysis is that, for
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parameter values informed by a range of in vitro and in vivo studies, the model predicts that
the maximum ECM volume fraction can generally be achieved by a relatively small volume
fraction of SMCs (e.g. < 20% even at moderate TGF-β concentrations). Interestingly, for
several of the numerical simulations presented in Section 3.2, the model predicts steady
state SMC volume fractions proximal to the endothelium that are above the level required
to maximise ECM deposition. Consequently, the steady state ECM levels in the cap region
in these simulations are typically smaller than their maximum possible level. With regard to
plaque stability, this outcome initially appears to be undesirable. However, note that a slight
excess in SMC numbers above the optimum level may be beneficial because it affords the
plaque greater robustness to destabilisation by mechanisms such as SMC loss or diminished
TGF-β signalling. When the typical steady state SMC volume fraction in the cap region
is below the level required for maximum ECM deposition, then an equivalent drop in SMC
numbers or loss of TGF-β signalling would have far more pronounced consequences for plaque
stability.
4.4 Numerical results agree with experimental observations
The base case simulation results reproduced several observations from experimental studies
of plaque growth in the ApoE-deficient mouse. For example, temporal changes in the model
plaque SMC and collagenous ECM levels were consistent with the qualitative pattern re-
ported in Reifenberg et al. (2012). The plaque SMC content accumulated rapidly over the
first 2 months of simulation time and maintained a relatively stable level thereafter. The
plaque ECM content, on the other hand, accumulated more slowly and eventually reached
a stable level after 4–6 months. The total SMC content and the total ECM content in the
model plaque after 4–8 months of simulation time were in good quantitative agreement with
the values reported in Reifenberg et al. (2012) and in other experimental studies (Mallat
et al., 2001; Clarke et al., 2006). An interesting aspect of the base case simulation was
that the total plaque SMC content reached a peak of around 9.2% after 4 months of sim-
ulation time and then dropped to around 8.6% as the plaque ECM content continued to
increase. This is a relatively subtle effect, but for simulations where the overall plaque ECM
content reaches higher levels (e.g. sensitivities with larger rs, smaller rd or smaller βρ), we
observe a more pronounced suppression of SMC numbers in the latter stages of cap forma-
tion (results not shown). These findings are consistent with observations made by Fukumoto
et al. (2004), who studied plaque growth in ApoE mice that were resistant to degradation of
type I collagen. Fukumoto et al. (2004) found that, relative to standard ApoE mice, these
compound-mutant mice had significantly more collagen and significantly fewer SMCs in their
plaques. Moreover, the plaques that were resistant to collagen degradation also showed ev-
idence of reduced SMC proliferation and increased SMC death. These observations suggest
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that excessive accumulation of collagen in plaques can tip the balance towards a net re-
duction in plaque SMC levels. The model presented here makes a similar prediction and
suggests that the loss of SMCs from collagen-rich plaques can be explained by an increase
in ECM-mediated contact inhibition of SMC proliferation and a decrease in the capacity for
PDGF transport in the dense intimal tissue.
A consistent finding throughout this modelling study is that the growth factor TGF-β
plays a critical role in the ability of plaque SMCs to deposit a stable, collagen-rich fibrous
cap. The analytical results in Section 3.1, for example, indicated that the presence of TGF-β
can enable significantly fewer SMCs to deposit significantly more ECM than would otherwise
be possible. These analytical results have been further supported by numerical simulations.
Compared to the base case, a sensitivity simulation with no TGF-β (αT = 0) showed an
overall decline in steady state plaque ECM levels, which included a substantial reduction
in ECM deposition in the cap region. These observations are qualitatively consistent with
those from equivalent experimental studies in ApoE mice (Mallat et al., 2001; Lutgens et al.,
2002). However, we also note some inconsistencies between the in vivo and in silico results.
For example, the model predicted a 15% decrease in plaque ECM content coupled to a 55%
increase in plaque SMC content, whereas both of the above experimental studies showed a
50% decrease in plaque collagen and no overall change in plaque SMC content after TGF-β
blockade. The reasons for these differences are not clear, but the experimental results also
showed that inhibition of TGF-β signalling led to increased inflammatory cell content and
larger lipid cores in the murine plaques. The SMC response in these in vivo plaques may
therefore have been blunted by increased competition for space or by increased SMC death in
the noxious and highly inflammatory plaque environment. The absence of these confounding
factors in the model could potentially explain why the plaque SMC and ECM content are
over-predicted in the current in silico approach.
In order for TGF-β to play its role in cap formation, PDGF is first required to stimulate
SMC recruitment to the cap region. PDGF may contribute both positively and negatively to
cap formation. Experimental evidence suggests that PDGF can increase SMC production of
matrix-degrading MMPs, in addition to stimulating SMC migration and SMC mitosis. These
factors were included in the model, and sensitivity simulations with different rates of PDGF
influx from the endothelium αP showed interesting results. For αP values in the range 0.3–
1.1, simulations showed that SMC recruitment to the cap region increased significantly with
increasing αP . ECM levels in the cap region close to steady state, on the other hand, were
relatively insensitive to αP and showed a biphasic response, with maximal ECM deposition
at the base case value (αP = 0.7). Note that these qualitative patterns of SMC and ECM
sensitivity to changes in αP have been shown to be independent of the corresponding rate
of TGF-β influx (for αT in the range 0–5).
The reported simulation with αP = 0.3 (and αT at its base case value) is interesting
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because it demonstrates that even a small amount of SMCs can generate a substantial
amount of ECM. From a total plaque SMC volume fraction of only 4.0% (vs. 8.6% in the
base case simulation), the total plaque ECM volume fraction reaches 15.0% (vs. 21.4% in
the base case simulation). This result is qualitatively consistent with observations made by
Clarke et al. (2006) in a study that examined the impact of diphtheria toxin (DT)-induced
SMC apoptosis in the plaques of ApoE mice. Plaque SMC content in DT treated mice
was reduced more than 4-fold relative to untreated mice (2.5% vs. 10.2%), but the plaque
collagen content was correspondingly reduced by just over 2-fold (8.0% vs. 18.1%). Of course,
despite the relatively small drop in the long-term plaque collagen content, the simulation
with αP = 0.3 also showed a significant delay in cap formation relative to the base case. This
simulation therefore provides a plausible explanation for the observations of Kozaki et al.
(2002), who studied the influence of PDGF blockade on cap formation in ApoE mice. In
this experimental study, two different techniques were used to inhibit PDGF signalling: (1)
development of transgenic ApoE mice with no PDGF expression in their circulating cells
and (2) treatment of standard ApoE mice with a PDGF receptor antagonist. The authors
indicated that PDGF signalling may only have been partially disrupted in each case, and
both methods were shown to delay rather than prevent cap formation. Kozaki et al. (2002)
did not report any data on the SMC content of the plaques in their study, but the reported
influence of PDGF inhibition on in vivo fibrous cap formation is entirely consistent with the
modelling results presented in this paper.
4.5 SMC haptotaxis and the problem of model ill-posedness
SMCs are well-known to respond haptotactically to gradients in collagenous substrates and
we have included this phenomenon in the model by assuming that the SMC phase has an
affinity for the ECM phase (quantified by the parameter χρ). Unlike SMC chemotaxis,
haptotactic SMC migration is not critical to the formation and maintenance of a cap in the
model. We therefore assumed a relatively low base case value for χρ, and later performed a
sensitivity study to investigate the impact of an increase in this value. The sensitivity study
emphasised the importance of SMC chemotaxis on the initiation of cap formation because,
even with a relatively large χρ value, it took over a month of simulation time for the nascent
ECM profile to have a discernible influence on the SMC phase. In the long term, the increase
in SMC haptotaxis led to steeper profiles in both the SMC and ECM phases in the plaque
but no overall increase in ECM deposition in the cap region. It would be interesting to
perform a more comprehensive investigation of the impact of the relative contributions of
SMC haptotaxis and SMC chemtotaxis on fibrous cap formation by simultaneously varying
the values of χρ and χP (or αP ). An in-depth investigation of the role of SMC haptotaxis
was not the primary intention of the current work, but the model presented herein creates
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the opportunity for a more focussed future study.
One reason why a thorough study of the role of SMC haptotaxis is challenging is that
the model equations can become ill-posed if the value assigned to χρ is too large. To un-
derstand why this is the case, consider the form of the effective SMC diffusion coefficient in
equation (39). This can be shown to be proportional to:
Λ + ρ
(
ψ +m
∂ψ
∂m
)
=
χP
1 + (κP )nP
− ρχρ +
δρmnρ
[
(1 + nρ) (1− ρ)−m
]
(1−m− ρ)nρ+1 . (57)
Note that the third term on the right hand side of this expression is strictly positive because
nρ > 0 and, by the no voids condition of equation (4), m < 1 − ρ. Recall that we have
assumed zero flux for SMCs at the endothelium (equation (31)). This boundary condition
stipulates that, at x = 0, any SMC flux towards the endothelium must be exactly balanced
by an equivalent SMC flux in the opposite direction. In practice, the chemotactic and hap-
totactic SMC fluxes almost always act towards the endothelium and this creates a negative
gradient in the SMC phase at x = 0. Hence, to satisfy the zero flux boundary condition at
x = 0, the diffusive SMC flux must always be positive and act down the SMC gradient away
from the endothelium. If the diffusive SMC flux becomes negative at any stage, the problem
immediately becomes ill-posed. Inspection of equation (57) indicates that negative SMC
diffusion can occur if the second term on the right hand side is dominant. This can occur if
SMC adhesion to the collagenous ECM is sufficiently strong to counteract the other mech-
anisms of cell spreading. Note that this scenario is particularly likely to occur if P is large
(first term on the right hand side of equation (57) negligible) and/or if m is small (third term
on the right hand side of equation (57) negligible). In general, it is difficult to remove this
problem of ill-posedness entirely, but here we propose several possible strategies to at least
reduce the region of parameter space where the problem occurs. First, we could regularise
the governing equations by including viscous effects in equation (11) for the SMC phase. Sec-
ond, as done by Byrne and Owen (2004), we could introduce a constant background SMC
diffusion by including an additional constant SMC phase pressure in the function Λ. Third,
we could assume that the SMC phase affinity for the ECM phase decreases with increasing
PDGF concentration (i.e. χρ ≡ χρ (P )). In this latter case, the first and second terms on the
right hand side of equation (57) would become complementary and, since we also assume
that SMC proliferation increases with increasing P , this would represent the introduction
of a “go-or-grow” mechanism in the SMC phase. Note, however, that the inclusion of a
P dependency in χρ would also introduce a new term into the effective SMC chemotaxis
coefficient. This term would resemble an ECM phase-dependent chemorepulsion. Of course,
the downside of these potential solutions to the problem of ill-posedness is that each solution
would introduce additional model parameters whose values may be difficult to determine in
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practice.
4.6 Implications for plaque destabilisation mechanisms
So, what conclusions can we draw from the model about factors that have been reported
to contribute to plaque instability? The model results suggest that, under conditions where
initial SMC recruitment is strong and plaque TGF-β levels remain favourable, the fibrous cap
should be robust to a relatively significant loss of SMC numbers. However, if as suggested
by Wang et al. (2015) that long-term loss of SMCs can occur due to replicative senescence,
the model would predict rapid degradation of the cap by immune cell activity as the SMC
population falls to critically low levels. In conditions where the SMC numbers and the TGF-
β concentration in the plaque remain at moderate levels, the current model suggests that
an increase in ECM degradation by immune cells alone is unlikely to destabilise the plaque.
In results that we have not reported in this paper, a sensitivity simulation with a 2-fold
increase in the baseline rate of ECM degradation by immune cells (βρ = 1.5) predicts only a
relatively small change in the ECM volume fraction in the cap region (32% vs. 38% in the
base case simulation). This makes sense because, based on our modelling assumptions, the
majority of the plaque immune cell content resides deeper in the plaque and beneath the cap
region. Of course, the current model is unable to predict the consequences of immune cell
ECM degradation at the plaque shoulders, where rupture events are commonly reported to
occur (Bennett et al., 2016). Investigation of this phenomenon will require models for cap
formation to be developed in two or three spatial dimensions.
The most critical factor in maintenance of plaque stability, as predicted by the current
model, is the continued presence of plaque TGF-β and, more importantly, the continued
capacity for stimulation of SMCs (and immune cells) by this growth factor. Our analysis
and our numerical simulations have indicated that TGF-β can play a critical role not only
in the formation of a stable cap region, but also in ensuring that cap formation is efficient
and does not require excessive recruitment of SMCs. Interestingly, recent reports from
in vivo and in vitro experiments have shown that cholesterol loading in several cell types,
including vascular SMCs, can significantly attenuate cellular responsiveness to TGF-β (Chen
et al., 2007; Vengrenyuk et al., 2015). Given the extent of cholesterol accumulation in the
intimal tissue during atherosclerotic plaque growth, it is therefore plausible that modified
LDL consumption by SMCs (and by macrophages) indirectly contributes to the breakdown of
plaque ECM by inhibiting the protective actions of TGF-β. Investigation of this hypothesised
cap destabilisation mechanism is another important target for future modelling studies.
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5 Conclusions
In this paper, we have developed a novel three-phase model of fibrous cap formation in
the atherosclerosis-prone mouse. The model investigates the roles of endothelium-derived
PDGF and TGF-β in the regulation of collagen cap deposition by synthetic vascular SMCs,
which migrate both chemotactically and haptotactically in the arterial intima. We have
parameterised the model using data from a wide range of in vitro and in vivo studies and
our numerical simulations reproduce a number of experimental observations. Our results
provide some interesting insights into potential mechanisms of plaque instability and long-
term cap degradation. The model presented in this paper can be extended in several new
directions, and this work therefore represents an important step in the development of a
dynamic and mechanistic understanding of atherosclerotic plaque formation.
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